Free Submission Public Relations & NewsPR-inside.com
 
DeutschEnglish

Get the latest news
with our RSS feed
rss feed
Add to My Yahoo!
More information
Business

Celsion Corporation Changes NASDAQ Ticker Symbol to 'CLSN'


Print article Print article
Refer this article Refer to a friend
© Business Wire 2008
2008-06-23 23:48:08 -

www.celsion.com - CELSION CORPORATION (NASDAQ: CLN) announced today the change of its NASDAQ stock ticker symbol from CLN to CLSN. The new ticker symbol will go into effect at the start of trading on June 30, 2008.

"We are pleased to announce our new ticker symbol, one that we believe will improve our visibility with investors

and more closely associate our company with the NASDAQ on which our shares have traded since February 2008," said Michael H. Tardugno, President and Chief Executive Officer of Celsion. "We continue to successfully execute on our strategy and our focus remains on building value for all shareholders."

About Celsion

Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic and the North Shore Long Island Jewish Health System. For more information on Celsion, visit our website: www.celsion.com. (CLN-W)

Cameron Associates
Paul G. Henning, 212-554-5462
phenning@cameronassoc.com


Disclaimer: (c) 2007 Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.


Terms & Conditions | About us | Contact PR-inside.com